222 related articles for article (PubMed ID: 10523893)
1. [Cancer of the prostate: advances in the use of PSA and its derived indices--new tumor markers].
Zlotta A; Schulman C
Rev Med Brux; 1999 Sep; 20(4):A201-5. PubMed ID: 10523893
[TBL] [Abstract][Full Text] [Related]
2. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.
Stephan C; Jung K; Lein M; Sinha P; Schnorr D; Loening SA
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1133-47. PubMed ID: 11097220
[TBL] [Abstract][Full Text] [Related]
3. Free and total human glandular kallikrein 2 in patients with prostate cancer.
Väisänen V; Pettersson K; Alanen K; Viitanen T; Nurmi M
Urology; 2006 Jul; 68(1):219-25. PubMed ID: 16844459
[TBL] [Abstract][Full Text] [Related]
4. [The search for better markers for prostate cancer than prostate-specific antigen].
Schenk-Braat EA; Bangma CH
Ned Tijdschr Geneeskd; 2006 Jun; 150(23):1286-90. PubMed ID: 16821452
[TBL] [Abstract][Full Text] [Related]
5. Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer.
Kamoi K; Babaian RJ
Semin Oncol; 1999 Apr; 26(2):140-9. PubMed ID: 10597725
[TBL] [Abstract][Full Text] [Related]
6. PSA and other tissue kallikreins for prostate cancer detection.
Stephan C; Jung K; Lein M; Diamandis EP
Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069
[TBL] [Abstract][Full Text] [Related]
7. [Prostate-specific antigen].
Eide IA; Angelsen A
Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2528-31. PubMed ID: 11070990
[TBL] [Abstract][Full Text] [Related]
8. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
9. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
Kuruma H; Egawa S
Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698
[TBL] [Abstract][Full Text] [Related]
10. The significance of prostate-specific antigen alpha-1-antichymotrypsin complex and its indices for the detection of prostate cancer.
Yamanaka K; Yamada Y; Kobayashi Y; Ueno K; Takechi Y; Hasegawa E; Chikahira Y
Hinyokika Kiyo; 2003 Jan; 49(1):5-10. PubMed ID: 12629773
[TBL] [Abstract][Full Text] [Related]
11. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
[TBL] [Abstract][Full Text] [Related]
12. [Significance of PSA-density: analysis in PSA gray zone cases].
Ishizuka O; Iwata K; Igawa Y; Nishizawa O
Hinyokika Kiyo; 2001 Sep; 47(9):611-3. PubMed ID: 11692595
[TBL] [Abstract][Full Text] [Related]
13. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
[TBL] [Abstract][Full Text] [Related]
14. Detecting prostate cancer by intracellular macrophage prostate-specific antigen (PSA): a more specific and sensitive marker than conventional serum total PSA.
Herwig R; Mitteregger D; Djavan B; Kramer G; Margreiter M; Leers MP; Glodny B; Haider DG; Hörl WH; Marberger M
Eur J Clin Invest; 2008 Jun; 38(6):430-7. PubMed ID: 18489403
[TBL] [Abstract][Full Text] [Related]
15. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
Tsuchiya N; Ohyama C; Habuchi T
Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
[TBL] [Abstract][Full Text] [Related]
16. PSA and PAP as immunohistochemical markers in prostate cancer.
Epstein JI
Urol Clin North Am; 1993 Nov; 20(4):757-70. PubMed ID: 7505984
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen in the diagnosis and staging of prostate cancer.
Jung P; Wolff JM; Mattelaer P; Jakse G
Acta Urol Belg; 1996 Sep; 64(3):1-6. PubMed ID: 8946774
[TBL] [Abstract][Full Text] [Related]
18. [Prostate specific antigen: a role of PSA in the diagnosis of prostate cancer].
Nutahara K; Higashihara E
Rinsho Byori; 2001 Oct; 49(10):963-6. PubMed ID: 11769472
[TBL] [Abstract][Full Text] [Related]
19. Beyond PSA: utility of novel tumor markers in the setting of elevated PSA.
Lin DW
Urol Oncol; 2009; 27(3):315-21. PubMed ID: 19414121
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Namba Y; Kishikawa H; Takahara S; Ichikawa Y
Prostate Cancer Prostatic Dis; 2008; 11(3):258-63. PubMed ID: 17876341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
